The programme is currently under development.


  • 4 Nov.   Morning: Satellites and workshops
  • 4 Nov.   Afternoon: Opening and plenary
  • 5 Nov.   Morning: Major sessions and abstract driven sessions
  • 5 Nov.   Afternoon: Abstract driven sessions and workshops
  • 6 Nov.   Morning: Major sessions and final plenary
  • 6 Nov.   Afternoon: Satellites and workshops


Programme committee

Eberhard Schatz / C-EHRN
Katrin Schiffer / C-EHRN
Antons Mojalevski / WHO Europe
Christos Anastasiou / EuroNPUD
Dagmar Hedrich / EMCDDA
Ganna Dovbakh / EHRA
Jeffrey Lazarus / ISGlobal
Jiri Richter / Sananim
Marie Jauffret Roustide / Inserm
Pavel Bem / Sananim
Peter Sarosi / Drugreporter
Tony Duffin / Ana Liffey

Conference Priorities

The conference programme aims to highlight innovative approaches in policy and practice as well as the latest research insights in the field of harm reduction.

There will be plenary and parallel sessions, round table discussions, workshops and other presentation formats to further discuss innovative developments in policy and practice of harm reduction, and to foster discussion and experience exchange.

Selection of priority topics:

 Harm Reduction in Policies:

  • Future of the EU Drug Policy
  • National Drug Policy Developments
  • Civil Society Involvement in Drug Policy (including Advocacy Case Studies)
  • Policy Reform – Newest Developments
  • Funding – Analysis and Innovative Experiences

Harm Reduction in Practice & Research

  • How do we transfer Models of Care and Good Practices?
  • Implementation of Quality Matters: Monitoring and Quality Standards
  • ‘Front Line Intelligence’ – the role of grass-root information for monitoring
  • Spreading harm reduction practices: The role of implementation science
  • OST best operational frameworks
  • HepC/Micro elimination – where are we regarding elimination targets?
  • Community-based services for People Who Use Drugs in prison
  • Meaningful involvement of communities in practice, research and policymaking

Harm Reduction interventions for non-injecting drug use

  • Harm reduction for cannabis
  • Harm reduction for cocaine and methamphetamine
  • Vaping: devices, products and risks

Innovation in Harm Reduction

  • Improving harm reduction through digital technology
  • New guidelines on drug equipment and materials
  • New ways for drug consumption rooms, Naloxone take-home programmes

Harm Reduction Expanded

  • Intersectional approaches, addressing the needs of people experiencing homelessness, sex workers, migrants, women and LGBTIQ
  • Facilitating collaboration between stakeholders on city level
  • Harm reduction beyond medicalisation: stigmatisation and human rights
  • Stimulant use and mental health

Addressing the harms of prohibition

  • ‘Drug-Related Intimidation’ (DRI) – what it means and how to respond
  • Upholding Human Rights
  • Harm reduction interventions for people who produce/transport/sell drugs
  • The role of law enforcement


European Harm Reduction Network

Tel. +31 20 570 7826 (direct)
c/o Foundation
Droogbak 1d
1013 GE Amsterdam
The Netherlands

With financial support of
the European Union

Share This